May 2021: Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

May 27, 2021

Article: Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis Published in: N Engl J Med. 2021;384(18):1705-1718. https://www.nejm.org/doi/full/10.1056/NEJMoa2033400 Authors: Dorman SE, Nahid P, Kurbatova EV, et al. Summary: The Tuberculosis...

Human Immunodeficiency Virus Infection in Adolescents and Mode of Transmission in Southern Africa: A Multinational Analysis of Population-Based Survey Data

May 10, 2021

Andrea Low, Chloe Teasdale, Kristin Brown, Danielle T Barradas, Owen Mugurungi, Karam Sachathep, Harriet Nuwagaba-Biribonwoha, Sehin Birhanu, Andrew Banda, Koen Frederix, Danielle Payne, Elizabeth Radin, Lubbe Wiesner, Choice Ginindza, Neena Philip, Godfrey Musuka,...

April 2021: IMPAACT 2010/VESTED trial evaluates the virological efficacy and safety of ART regimens containing DTG when started in pregnancy

Apr 29, 2021

Article: Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT...

Low Disclosure of PrEP nonadherence and HIV risk behaviors associated with poor HIV PrEP adherence in the HPTN 067/ADAPT Study

May 21, 2019

Victoria D O, Rivet AK, James P H, Ethan W, Maoji L, Timothy H H, Anupong C, Robert M G, Bonnie D, Linda-Gail B, Sharon M, Mark M, Craig W H. J Acquir Immune Defic Syndr. 2019 May 21. doi: 10.1097/QAI.0000000000002103. [Epub ahead of print] Abstract OBJECTIVE:...

MTCT-Plus End-of-Project Reports

Aug 14, 2018

The MTCT-Plus Initiative, the world’s first multi-country HIV treatment program, aimed to demonstrate to a disbelieving world that it was possible to provide care and antiretroviral (ARV) treatment in resource-limited settings, using programs to prevent...

Thailand